ATE274921T1 - Verfahren zur selektion von fxr- rezeptormodulatoren - Google Patents

Verfahren zur selektion von fxr- rezeptormodulatoren

Info

Publication number
ATE274921T1
ATE274921T1 AT00918345T AT00918345T ATE274921T1 AT E274921 T1 ATE274921 T1 AT E274921T1 AT 00918345 T AT00918345 T AT 00918345T AT 00918345 T AT00918345 T AT 00918345T AT E274921 T1 ATE274921 T1 AT E274921T1
Authority
AT
Austria
Prior art keywords
selecting
fxr
receptor modulators
fxr receptor
methods
Prior art date
Application number
AT00918345T
Other languages
English (en)
Inventor
Barry M Forman
Haibo Wang
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE274921T1 publication Critical patent/ATE274921T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Toxicology (AREA)
AT00918345T 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren ATE274921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12633499P 1999-03-26 1999-03-26
PCT/US2000/007836 WO2000057915A1 (en) 1999-03-26 2000-03-24 Method of affecting cholesterol catabolism using nuclear bile acid receptor

Publications (1)

Publication Number Publication Date
ATE274921T1 true ATE274921T1 (de) 2004-09-15

Family

ID=22424256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00918345T ATE274921T1 (de) 1999-03-26 2000-03-24 Verfahren zur selektion von fxr- rezeptormodulatoren
AT04075173T ATE330632T1 (de) 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04075173T ATE330632T1 (de) 1999-03-26 2000-03-24 Selektion von fxr-rezeptormodulatoren

Country Status (7)

Country Link
EP (1) EP1165135B1 (de)
JP (1) JP2004510682A (de)
AT (2) ATE274921T1 (de)
AU (1) AU780658B2 (de)
CA (1) CA2368234A1 (de)
DE (2) DE60013417T2 (de)
WO (1) WO2000057915A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
WO2002022817A2 (en) * 2000-09-16 2002-03-21 Lion Bioscience Ag Nuclear receptor l66 and methods of use
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
EP1465882B1 (de) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
JP4928260B2 (ja) * 2004-04-23 2012-05-09 武田薬品工業株式会社 新規スクリーニング方法
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 lxr 변조제
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
MY153958A (en) 2009-05-28 2015-04-30 Exelixis Patent Co Llc Lxr modulators
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
PT2758060T (pt) * 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
US11208664B2 (en) 2016-09-12 2021-12-28 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6516094A (en) * 1993-02-05 1994-08-29 Board Of Regents, The University Of Texas System Cholesterol 7-alpha hydroxylase expression regulation
JP2002515856A (ja) * 1995-10-11 2002-05-28 タラリア セラピューティックス インコーポレーテッド リポソーム組成物およびそれらの利用方法
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
IL126045A0 (en) * 1996-03-20 1999-05-09 Dyax Corp Purification of tissue plasminogen activator (tpa)

Also Published As

Publication number Publication date
EP1165135B1 (de) 2004-09-01
JP2004510682A (ja) 2004-04-08
EP1165135A1 (de) 2002-01-02
AU780658B2 (en) 2005-04-07
DE60029029T2 (de) 2007-06-14
DE60029029D1 (de) 2006-08-03
DE60013417T2 (de) 2005-09-15
CA2368234A1 (en) 2000-10-05
WO2000057915A1 (en) 2000-10-05
AU3917300A (en) 2000-10-16
DE60013417D1 (de) 2004-10-07
ATE330632T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
DE60013417D1 (de) Verfahren zur selektion von fxr-rezeptormodulatoren
WO2003030612A3 (en) Methods for modulating activity of the fxr nuclear receptor
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE298248T1 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE60132624D1 (de) Verfahren zum verteilen von werbung unter verwendung einer eingebetteten medien-abspielerseite
NO960767L (no) Protocadherinproteiner og deres anvendelse
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
ATE517123T1 (de) Anti-gpr-9-6 und anti-teck gerichtete antikörper und verfahren zur identifizierung von modulatoren der gpr-9-6 und teck funktion
ATE303992T1 (de) Verfahren zur herstellung von nichtsteroidale glucocorticoidrezeptor- modulatoren
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
ZA9610080B (en) Screening assay for compounds stimulating somatostatin and insulin production.
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
WO1999050440A3 (en) Method to identify modulators of survivin - tubulin interaction
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
ATE321887T1 (de) Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
DE60328932D1 (de) Verfahren und Reaktor zur Durchführung von Rezeptor-Ligand Bindungsreaktionen
DE60302263D1 (de) Verfahren zur Durchführung von Rezeptor-Ligand Bindungsreaktionen
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator
EP0985045B1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
WO2004018632A3 (en) High-throughput screen for modulators of chromatin modifying activity
ATE305521T1 (de) Verfahren zur bindung von nukleinsäuren an einen träger
ATE440613T1 (de) Androgen-reguliertes pmepa1 gen und verfahren zu seiner verwendung zur hemmung von krebszellwachstum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties